1085706-72-4

Upstream product

• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 1085706-70-2 (S)-tert-butyl 2-(5-(4'-(5-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-2-yl)biphenyl-4-yl)oxazol-2-yl)pyrrolidine-1-carboxylate 
• 1085706-69-9 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxazol-2-yl)pyrrolidine-1-carboxylate 
• 1085706-68-8 (S)-tert-butyl 2-(5-(4-bromophenyl)oxazol-2-yl)pyrrolidine-1-carboxylate 
• 72-18-4 L-valine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1007881-98-2 y 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.